Читать книгу Complementary and Alternative Medicine (CAM) Supplement Use in People with Diabetes: A Clinician's Guide - Laura Shane-McWhorter - Страница 23

Gymnema has been studied for up to 2 years in both type 1 and type 2 diabetes. Target goals for A1C and fasting glucose have not been achieved in published studies. Gymnema has a variety of actions that may stimulate glucose uptake and utilization as well as stimulate β-cell function. If gymnema is used, a standardized extract should be chosen. This product has not been studied in pregnant or lactating women, children, or elderly and therefore should not be used in these populations. The main potential adverse effect is hypoglycemia; hence it is important that medical providers supervise their patients’ use of this product and possibly consider decreasing the dose of concomitant secretagogues. A standardized gymnema extract is being studied in the U.S. A typical dose is 400 mg/day, standardized to contain 24% gymnemic acids.¹⁹